scholarly journals On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry

2016 ◽  
Vol 14 (11) ◽  
pp. 1379-1388 ◽  
Author(s):  
Alberto Carmona-Bayonas ◽  
Paula Jiménez-Fonseca ◽  
Maria Luisa Sánchez Lorenzo ◽  
Avinash Ramchandani ◽  
Elena Asensio Martínez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Registry ◽  
National Cancer Registry ◽  
Doublet Chemotherapy

scholarly journals Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry

2017 ◽  
Vol 28 ◽  
pp. v231
Author(s):  
A. Carmona-Bayonas ◽  
P. Jiménez-Fonseca ◽  
R. Hernández ◽  
A. Custodio ◽  
J.M. Cano ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Registry ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
National Cancer Registry

scholarly journals Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation

2017 ◽  
Vol 37 (1) ◽  
pp. 309-314 ◽  
Author(s):  
KEIJI SUGIYAMA ◽  
YUKIYA NARITA ◽  
SHIGENORI KADOWAKI ◽  
TAKASHI URA ◽  
MASAHIRO TAJIKA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Disseminated Intravascular Coagulation ◽  
Intravascular Coagulation ◽  
Doublet Chemotherapy

scholarly journals First-line triplet or doublet chemotherapy for advanced gastric cancer: Analysis of 970 patients from a community practice registry

2016 ◽  
Vol 27 ◽  
pp. vi212 ◽  
Author(s):  
I. Echavarria Diaz-Guardamino ◽  
A. Carmona-Bayonas ◽  
P. Jimenez Fonseca ◽  
A.J. Muñoz Martin ◽  
M.L. Sanchez Lorenzo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Community Practice ◽  
First Line ◽  
Doublet Chemotherapy

scholarly journals A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Xinjian Guo ◽  
Fuxing Zhao ◽  
Xinfu Ma ◽  
Guoshuang Shen ◽  
Dengfeng Ren ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Advanced Gastric Cancer ◽  
Meta Analysis ◽  
Objective Response ◽  
Progression Free Survival ◽  
Controlled Trials ◽  
Triplet Chemotherapy ◽  
Asian Patients ◽  
Doublet Chemotherapy

Abstract Background Chemotherapy can improve the survival of patients with advanced gastric cancer. However, whether triplet chemotherapy can further improve the survival of patients with advanced gastric cancer compared with doublet chemotherapy remains controversial. This study reviewed and updated all published and eligible randomized controlled trials (RCTs) to compare the efficacy, prognosis, and toxicity of triplet chemotherapy with doublet chemotherapy in patients with advanced gastric cancer. Methods RCTs on first-line chemotherapy in advanced gastric cancer on PubMed, Embase, and the Cochrane Register of Controlled Trials and all abstracts from the annual meetings of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology conferences up to October 2018 were searched. The primary outcome was overall survival, while the secondary outcomes were progression-free survival (PFS), time to progress (TTP), objective response rate (ORR), and toxicity. Results Our analysis included 23 RCTs involving 4540 patients and 8 types of triplet and doublet chemotherapy regimens, and systematic review and meta-analysis revealed that triplet chemotherapy was superior compared with doublet chemotherapy in terms of improving median OS (HR = 0.92; 95% CI, 0.86–0.98; P = 0.02) and PFS (HR = 0.82; 95% CI, 0.69–0.97; P = 0.02) and TTP (HR = 0.92; 95% CI, 0.86–0.98; P = 0.02) and ORR (OR = 1.21; 95% CI, 1.12–1.31; P < 0.0001) among overall populations. Compared with doublet chemotherapy, subgroup analysis indicated that OS improved with fluoropyrimidine-based (HR = 0.80; 95% CI, 0.66–0.96; P = 0.02), platinum-based (HR = 0.75; 95% CI, 0.57–0.99; P = 0.04), and other drug-based triplet (HR = 0.79; 95% CI, 0.69–0.90; P = 0.0006) chemotherapies while not with anthracycline-based (HR = 0.70; 95% CI, 0.42–1.15; P = 0.16), mitomycin-based (HR = 0.81; 95% CI, 0.47–1.39; P = 0.44), taxane-based (HR = 0.91; 95% CI, 0.81–1.01; P = 0.07), and irinotecan-based triplet (HR = 1.01; 95% CI, 0.82–1.24; P = 0.94) chemotherapies. For different patients, compared with doublet chemotherapy, triplet chemotherapy improved OS (HR = 0.89; 95% CI, 0.81–0.99; P = 0.03) among Western patients but did not improve (HR = 0.96; 95% CI, 0.86–1.07; P = 0.47) that among Asian patients. Conclusions Compared with doublet chemotherapy, triplet chemotherapy improved OS, PFS, TTP, and ORR in patients with advanced gastric cancer in the population overall, and improved OS in Western but not in Asian patients.

scholarly journals Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry

Oncotarget ◽  
2016 ◽  
Vol 7 (24) ◽  
pp. 35853-35864 ◽  
Author(s):  
Jianjun Liu ◽  
Qirong Geng ◽  
Zhimin Liu ◽  
Shangxiang Chen ◽  
Jing Guo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Registry ◽  
External Validation ◽  
National Cancer Registry
Sign in / Sign up

Export Citation Format

Share Document